Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase. It is grouped under the following drug class(es): Kinase inhibitors. Its therapeutic use is listed as hematologic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Tavalisse, fostamatinibum and Fostatinib. Its PubChem CID is 11671467.
Fostamatinib
| CAS No | 901119-35-5 |
|---|---|
| Molecular Formula | C23H26FN6O9P |
| Molecular Weight | 580.50 g/mol |
| Synonyms | [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP.
The listed CAS number is 901119-35-5.
The listed molecular formula is C23H26FN6O9P.
The listed molecular weight is 580.50 g/mol.
[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl dihydrogen phosphate.
The source lists Tavalisse, fostamatinibum and Fostatinib.